BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 236 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $248 | +55.0% | 40,159 | +77.6% | 0.03% | +75.0% |
| Q3 2023 | $160 | -41.4% | 22,609 | -41.8% | 0.02% | -52.9% |
| Q2 2023 | $273 | -99.9% | 38,825 | +42.4% | 0.03% | +3.0% |
| Q2 2022 | $288,000 | -1.7% | 27,257 | +51.3% | 0.03% | -5.7% |
| Q1 2022 | $293,000 | -23.9% | 18,017 | -32.7% | 0.04% | -23.9% |
| Q3 2021 | $385,000 | +296.9% | 26,774 | +32.0% | 0.05% | +206.7% |
| Q2 2020 | $97,000 | -2.0% | 20,284 | -58.9% | 0.02% | -21.1% |
| Q1 2020 | $99,000 | -18.9% | 49,335 | +207.7% | 0.02% | +11.8% |
| Q3 2018 | $122,000 | -15.3% | 16,036 | -38.0% | 0.02% | -37.0% |
| Q2 2017 | $144,000 | -57.3% | 25,885 | -35.6% | 0.03% | -65.8% |
| Q1 2017 | $337,000 | +524.1% | 40,190 | +110.3% | 0.08% | +426.7% |
| Q1 2016 | $54,000 | -74.9% | 19,107 | +32.7% | 0.02% | -80.0% |
| Q2 2015 | $215,000 | – | 14,397 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
| Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
| Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
| Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
| ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
| TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
| MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
| Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
| Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
| Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |